Oral cancer is the sixth most common type of cancer worldwide and in the U.S., one person dies every hour from the disease. According to American Cancer Society data, nearly as many women will be diagnosed with oral cancer as with cervical cancer this year. The key to reducing the impact of this disease is early detection.
New cancer drugs taken in pill form have become dramatically more expensive in their first year on the market compared with drugs launched 15 years ago, a University of North Carolina at Chapel Hill study has found. The findings call into question the sustainability of a system that sets high prices at market entry in addition to rapidly increasing those prices over time.
A new study provides insight on the potential role played by RNA (ribonucleic acid) editing in cancer. The findings, which appear online in the journal Scientific Reports, may further our understanding of an emerging mechanism implicated in tumor initiation and progression, and may thus lead to the development of better treatment options in the future.
Head and neck cancers (HNC) are the sixth most common cancers worldwide, with approximately 600,000 new cases diagnosed every year.
Europe’s largest dental treatment provider, mydentist, is calling on smokers across the UK to quit on No Smoking Day for the good of their oral health.
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at The Johns Hopkins University.
Researchers at the University of Iowa College of Dentistry are partnering with a private company to develop computer simulations that can help personalize cancer care by predicting how a patient will respond to a drug treatment.
A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.
Researchers at Simon Fraser University and the BC Cancer Agency have developed a groundbreaking method to identify and separate stem cells that reside in the tonsils. Their research, which sheds new light on the fight against oral cancer, is published today in the journal Stem Cell Reports.
For hundreds of millions of people around the world, chewing betel nut produces a cheap, quick high but also raises the risk of addiction and oral cancer. Now, new findings by a University of Florida Health researcher reveal how the nut's psychoactive chemical works in the brain and suggest that an addiction treatment may already exist.
High school athletes who play on sports teams smoke tobacco products at a lower rate than non-athletes, but use smokeless tobacco at a higher rate, according to a study published by the Centers for Disease Control and Prevention in today's Morbidity and Mortality Weekly Report (MMWR).
An abnormal immune response or "feedback loop" could very well be the underlying cause of metastases in oral cancers, according to Dr. Marco Magalhaes, Assistant Professor at the University of Toronto's Faculty of Dentistry and lead researcher in a study published in the journal Cancer Immunology Research.
Oropharyngeal cancer patients who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva following cancer treatment are at an increased risk for recurrence, a study led by researchers at the Johns Hopkins Bloomberg School of Public Health has found.
Taiho Pharmaceutical Co., Ltd.(Japan) and Servier (France) announced on June 15 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in Europe and other countries.
Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.
Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.
Researchers at Oregon State University are pursuing a new concept in treatment of epithelial cancer, especially head and neck cancer, by using two promising "analogs" of an old compound that was once studied as a potent anti-tumor agent, but long ago abandoned because it was too toxic.
Mouth and throat cancers are the fastest rising cancers today. They account for over 40,000 cases per year in the U.S. The American Cancer Society estimates that there will be 121,790 new cases of head and neck cancer diagnosed in 2015 and 14,240 deaths. These numbers include tongue cancer, throat cancers caused by the human papillomavirus or HPV, voice box cancer, melanoma of the face and thyroid cancers.
When oral and oropharyngeal cancers (cancers of the mouth and upper throat) are detected and treated early in their development, survival rates can improve significantly. Regular oral cancer examinations performed by your oral health professional remain the best method for detecting oral cancer in its early stages.
A compound found in green tea may trigger a cycle that kills oral cancer cells while leaving healthy cells alone, according to Penn State food scientists. The research could lead to treatments for oral cancer, as well as other types of cancer.
Improving oral health is a leading population health goal; however, curricula preparing health professionals have a dearth of oral health content and clinical experiences. Funded by a grant from the Health Resources and Service Administration, New York University College of Nursing's Teaching Oral-Systemic Health Program is working to build interprofessional oral health workforce capacity which addresses a significant public health issue, increases oral health care access, and improves oral-systemic health across the lifespan.